AMENDMENTS TO THE CLAIMS

Claim 1 (Previously Presented) An oral vaccine composition against diarrhea caused by enterotoxigenic *E. coli*, which comprises at least three different types of colonization factor antigens (CFAs) selected from the group consisting of CFA I, CFA II (CS1, CS2 and CS3) and CFA IV (CS4, CS5 and CS6), on killed *E. coli* bacteria lacking the gene encoding the heat labile enterotoxin (LT), together with the B-subunit of cholera toxin (CTB), and a physiologically acceptable vehicle, which vaccine composition does not contain heat stable enterotoxin (ST).

Claims 2-4 (Cancelled).

Claim 5 (New) The oral vaccine according to claim 1 wherein the vaccine comprises five enterotoxigenic *E. coli* (ETEC) bacterial strains.

Claim 6 (New) The vaccine according to claim 1 wherein the vaccine comprise

(i) An enterotoxigenic *E. coli* (ETEC) bacterial strain expressing CFA/I (SBL101)

(ii) An enterotoxigenic *E. coli* (ETEC) bacterial strain expressing CFA/II (CS1) (SBL 106)

(iii) An enterotoxigenic E. coli (ETEC) bacterial strain expressing CFA/II (CS2+CS3) (SBL 107)

(iv) An enterotoxigenic E. coli (ETEC) bacterial strain expressing CFA/IV (CS4+CS6) (SBL 104); and

(v) An E. coli bacterial strain expressing CFA/IV (CS5+CS6) (SBL 105)

Claim 7 (New) The vaccine according to claim 5 wherein the vaccine comprise

(i) An enterotoxigenic *E. coli* (ETEC) bacterial strain expressing CFA/I (SBL101)

(ii) An enterotoxigenic *E. coli* (ETEC) bacterial strain expressing CFA/II (CS1) (SBL 106)

(iii) An enterotoxigenic E. coli (ETEC) bacterial strain expressing CFA/II (CS2+CS3) (SBL 107)

(iv) An enterotoxigenic E. coli (ETEC) bacterial strain expressing CFA/IV (CS4+CS6) (SBL 104); and

(v) An E. coli bacterial strain expressing CFA/IV (CS5+CS6) (SBL 105)

Claim 8 (New) The oral vaccine according to claim 1, wherein the vaccine comprises at least 100 μg of each type of CFA, and at least 0.5 mg of CTB, and the vehicle is a buffer solution.

Claim 9 (New) The oral vaccine according to claim 8, wherein the vaccine comprises 100 to 300 μg of each type of CFA, and 0.5 to 2.0 mg of CTB.

Claim 10 (New) The oral vaccine according to claim 9, wherein the vaccine comprises 200 μg of CFA/I, 200 μg of CS1, 150 μg of CS2, 200 μg of CS4, 150 μg of CS5, and 1.0 mg of CTB, and the buffer solution is phosphate buffered saline solution.

Claim 11 (New) The oral vaccine according to any one of claims 1 and 5-10 wherein the CTB is recombinant CTB (rCTB).

Claim 12 (New) The oral vaccine according to claim 11 wherein 1 mg of rCTB is used.

Claim 13 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 1 to said individual.

Claim 14 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 5 to said individual.

Claim 15 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 6 to said individual.

Claim 16 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 7 to said individual.

Claim 17 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 8 to said individual.

Claim 18 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 9 to said individual.

Claim 19 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 10 to said individual.

Claim 20 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 11 to said individual.

Claim 21 (New) A method of vaccinating an individual against diarrhea wherein the method comprises administering the vaccine of claim 12 to said individual.

Claim 22 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 1 to said human.

Claim 23 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 5 to said human.

Claim 24 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 6 to said human.

Claim 25 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 7 to said human.

Claim 26 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 8 to said human.

Claim 27 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 9 to said human.

Claim 28 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 10 to said human.

Claim 29 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 11 to said human.

Claim 30 (New) A method for preventing an enteric infection in a human caused by enterotoxigenic *E. coli* bacterial (ETEC) which comprises administering the vaccine of claim 12 to said human.

Claim 31 (New) The method according to claim 22 wherein the ETEC bacteria are ST only producing bacteria.

Claim 32 (New) The method according to claim 23 wherein the ETEC bacteria are ST only producing bacteria.

Claim 33 (New) The method according to claim 24 wherein the ETEC bacteria are ST only producing bacteria.

Claim 34 (New) The method according to claim 25 wherein the ETEC bacteria are ST only producing bacteria.

Claim 35 (New) The method according to claim 26 wherein the ETEC bacteria are ST only producing bacteria.

Claim 36 (New) The method according to claim 27 wherein the ETEC bacteria are ST only producing bacteria.

Claim 37 (New) The method according to claim 28 wherein the ETEC bacteria are ST only producing bacteria.

Claim 38 (New) The method according to claim 29 wherein the ETEC bacteria are ST only producing bacteria.

Claim 39 (New) The method according to claim 30 wherein the ETEC bacteria are ST only producing bacteria.